BioCentury | Apr 15, 2021

Genechem’s bispecifics deal with I-Mab marks debut for a global strategy 20 years in the making

A deal with I-Mab is one of what Genechem hopes will be many to leverage an antibody discovery platform that it’s been building for the past five years. Shanghai Genechem Co. Ltd. and I-Mab...
BioCentury | Apr 13, 2021

Competence & continuity at CDER; plus BIO 3.0, AACR and 2Q preview: a BioCentury podcast

On the latest BioCentury This Week podcast, BioCentury editors discuss what Patrizia Cavazzoni’s appointment as permanent director of FDA’s Center for Drug Evaluation and Research means for the biopharma...
BioCentury | Apr 7, 2021
Management Tracks

Takeda’s Koo to lead Overland-ADC joint venture; plus Precision, Amryt, Bridge, Opthea and Cogent

Eric Koo will become CEO of Overland ADCT BioPharma (CY) Ltd., the joint venture between Overland Pharmaceuticals and ADC Therapeutics S.A. (NYSE:ADCT) that launched in December. The JV is developing ADC Therapeutics’ loncastuximab tesirine, a pyrrolobenzodiazepine (PBD) dimer-linked...
BioCentury | Apr 2, 2021
Product Development

Chinese biotechs look to next-generation CAR T technologies to solve market challenges

Though nearly every Chinese CAR T developer is prioritizing autologous programs, the key to expanding access to the modality on the price-sensitive China market is likely to be the next-generation platforms...
BioCentury | Mar 30, 2021

Abernethy and the obvious at FDA; plus CEPI and EpimAb: a BioCentury podcast

Amy Abernethy set out to tackle “the blooming obvious” issues faced by FDA when she joined the agency two years ago. In the latest BioCentury This Week podcast, BioCentury’s editors discuss the key takeaways from...
BioCentury | Mar 30, 2021
Management Tracks

Li departs LianBio as CEO; plus Xilio, Myriad, OKYO and Intravacc

Bing Li has left Perceptive Advisors-backed cross-border company LianBio as CEO, according to his LinkedIn page. Li’s previous roles include CEO of China Biologic Products Holdings Inc. (NASDAQ:CBPO), chairman of Ambrx Inc. and managing director and...
BioCentury | Mar 23, 2021
Product Development

FTC & the zombie pharma dinosaurs, plus RIP José Baselga, NCATS & SPACs: a BioCentury podcast

On the latest BioCentury This Week podcast, BioCentury’s editors discuss the legacy of AstraZeneca’s José Baselga as well as the next steps for the U.K. pharma after releasing data from the U.S. trial...
BioCentury | Mar 16, 2021

Vaccine vexed; plus assessing Lilly’s Alzheimer’s data & PDUFA preview: a BioCentury podcast

The only thing that’s clear from the latest big Alzheimer’s readout is that the entrenched camps of amyloid believers and doubters will take predictably polarized views. On the latest BioCentury This Week...
BioCentury | Mar 13, 2021
Product Development

Long COVID therapies are starting to populate a sparse pipeline

As Long COVID research ramps up, the first set of therapeutic candidates are either geared toward organ-centered pathology shared with other diseases, or viral and immune mechanisms that could be unifying...
BioCentury | Mar 9, 2021
Product Development

New modality deep dive; plus Sharpless speaks & Five Prime scores: a BioCentury podcast

On the latest BioCentury This Week podcast, BioCentury’s editors discuss take-homes from a discussion with NCI Director Ned Sharpless, who talked to BioCentury  about how he thinks FDA could expedite reviews of cancer and rare...
Items per page:
1 - 10 of 1801